DE19925143A1 - Neue liposomale Vektorkomplexe und deren Verwendung für die Gentherapie - Google Patents

Neue liposomale Vektorkomplexe und deren Verwendung für die Gentherapie

Info

Publication number
DE19925143A1
DE19925143A1 DE19925143A DE19925143A DE19925143A1 DE 19925143 A1 DE19925143 A1 DE 19925143A1 DE 19925143 A DE19925143 A DE 19925143A DE 19925143 A DE19925143 A DE 19925143A DE 19925143 A1 DE19925143 A1 DE 19925143A1
Authority
DE
Germany
Prior art keywords
component
liposomal vector
complex according
complex
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19925143A
Other languages
German (de)
English (en)
Inventor
Sabine Bruesselbach
Kristina Mueller
Alfred Fahr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Priority to DE19925143A priority Critical patent/DE19925143A1/de
Priority to PCT/EP2000/004678 priority patent/WO2000074646A2/de
Priority to CA002375854A priority patent/CA2375854A1/en
Priority to AU47583/00A priority patent/AU4758300A/en
Priority to EP00929548A priority patent/EP1187929A2/de
Priority to JP2001501183A priority patent/JP2003501373A/ja
Publication of DE19925143A1 publication Critical patent/DE19925143A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19925143A 1999-06-02 1999-06-02 Neue liposomale Vektorkomplexe und deren Verwendung für die Gentherapie Withdrawn DE19925143A1 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE19925143A DE19925143A1 (de) 1999-06-02 1999-06-02 Neue liposomale Vektorkomplexe und deren Verwendung für die Gentherapie
PCT/EP2000/004678 WO2000074646A2 (de) 1999-06-02 2000-05-23 Neue liposomale vektorkomplexe und deren verwendung für die gentherapie
CA002375854A CA2375854A1 (en) 1999-06-02 2000-05-23 Novel liposomal vector complexes and their use in gene therapy
AU47583/00A AU4758300A (en) 1999-06-02 2000-05-23 Novel liposomal vector complexes and their use in gene therapy
EP00929548A EP1187929A2 (de) 1999-06-02 2000-05-23 Neue liposomale vektorkomplexe und deren verwendung für die gentherapie
JP2001501183A JP2003501373A (ja) 1999-06-02 2000-05-23 新規なリポソームベクター複合体および遺伝子療法でのそれらの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19925143A DE19925143A1 (de) 1999-06-02 1999-06-02 Neue liposomale Vektorkomplexe und deren Verwendung für die Gentherapie

Publications (1)

Publication Number Publication Date
DE19925143A1 true DE19925143A1 (de) 2000-12-07

Family

ID=7909923

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19925143A Withdrawn DE19925143A1 (de) 1999-06-02 1999-06-02 Neue liposomale Vektorkomplexe und deren Verwendung für die Gentherapie

Country Status (6)

Country Link
EP (1) EP1187929A2 (ja)
JP (1) JP2003501373A (ja)
AU (1) AU4758300A (ja)
CA (1) CA2375854A1 (ja)
DE (1) DE19925143A1 (ja)
WO (1) WO2000074646A2 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053937A2 (en) * 2007-10-25 2009-04-30 Universidade De Coimbra Nano-lipid-based carriers for targeted delivery of viral vectors and process for its production
CN101270168B (zh) * 2008-05-13 2011-06-22 中国药科大学 透明质酸接枝聚乙烯亚胺共聚物、制备方法及其作为基因载体的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9387152B2 (en) 2010-06-28 2016-07-12 The General Hospital Corporation Blood substitutes and uses thereof
EP3538546A1 (en) 2016-11-14 2019-09-18 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
EP0784984B1 (en) * 1996-01-17 2003-07-02 F. Hoffmann-La Roche Ag Transfection competent molecules
NZ500694A (en) * 1997-04-30 2001-09-28 Univ Minnesota Use of chimeric mutational vector (CMV), a macromolecule and a ligand for cell surface receptor adhesion molecule (clatherin) in gene therapy; the CMV vector derived from REC2 homologous pairing with Ustilago maydis
AU3706599A (en) * 1998-04-07 1999-10-25 Roche Diagnostics Gmbh New compounds for dna-transfection
JP2002520038A (ja) * 1998-07-20 2002-07-09 アイネックス ファーマシューティカルズ コーポレイション リポソームカプセル化核酸複合体

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053937A2 (en) * 2007-10-25 2009-04-30 Universidade De Coimbra Nano-lipid-based carriers for targeted delivery of viral vectors and process for its production
WO2009053937A3 (en) * 2007-10-25 2009-06-11 Univ De Coimbra Nano-lipid-based carriers for targeted delivery of viral vectors and process for its production
CN101270168B (zh) * 2008-05-13 2011-06-22 中国药科大学 透明质酸接枝聚乙烯亚胺共聚物、制备方法及其作为基因载体的应用

Also Published As

Publication number Publication date
WO2000074646A3 (de) 2001-08-09
EP1187929A2 (de) 2002-03-20
JP2003501373A (ja) 2003-01-14
AU4758300A (en) 2000-12-28
CA2375854A1 (en) 2000-12-14
WO2000074646A2 (de) 2000-12-14

Similar Documents

Publication Publication Date Title
Li et al. Intracellular delivery and biodistribution study of CRISPR/Cas9 ribonucleoprotein loaded bioreducible lipidoid nanoparticles
McCarthy et al. Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery
DE69725877T2 (de) Kationische lipid-nukleinsäure komplexe
DE69906977T2 (de) In liposomen verkapselte nukleinsäurekomplexe
JP5480764B2 (ja) 両性リポソーム及びその使用
DE69535540T2 (de) Zusammensetzung enthaltend nukleinsäuren und kationische polymere, zubereitung und verwendung
DE69634084T2 (de) Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
Algarni et al. In vivo delivery of plasmid DNA by lipid nanoparticles: the influence of ionizable cationic lipids on organ-selective gene expression
Jiang et al. The in vivo fate and targeting engineering of crossover vesicle-based gene delivery system
Li et al. Non-viral strategies for delivering genome editing enzymes
DE69826488T2 (de) Stabile partikuläre komplexe lamellarer struktur mit neutraler oder negativer gesamtladung
DE69837819T2 (de) Kondensierte plasmid-liposome komplex zur transfektion
WO2014057432A9 (en) Multicomponent lipid nanoparticles and processes for the preparation thereof
EP0905254A2 (de) Mit biologisch verträglichen niedermolekularen Polyethyleniminen assoziierte DNA-Vektor
Golkar et al. Modulated cellular delivery of anti-VEGF siRNA (bevasiranib) by incorporating supramolecular assemblies of hydrophobically modified polyamidoamine dendrimer in stealth liposomes
US20150050330A1 (en) Compositions and methods for polymer-caged liposomes
CN111386105B (zh) 用于递送生物活性分子的膜融合化合物
DE60014133T2 (de) Lipid zur Verwendung in einer Liposomzusammensetzung zur Abgabe eines Mittels an eine Zelle
WO2011003406A2 (de) Mischung amphipathischer moleküle und verfahren zur zellmembranmodifikation durch fusion
Berger et al. Poly (vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery
CN107867677A (zh) 一维磷酸钙纳米/微米材料及其制备方法和应用
WO2023093596A1 (zh) 一种用于有效递送核酸的环状多肽载体及其变化形式
DE19925143A1 (de) Neue liposomale Vektorkomplexe und deren Verwendung für die Gentherapie
EP1063254A1 (de) Copolymere für den Transport von Nukleinsäuren in die Zelle
US20050180922A1 (en) Block co-polymer worm micelles and methods of use therefor

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee